Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0630

-1.6%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Littlebits	5/31/2012 9:46:22 AM
	of 13111

pharmalot.com Not surprisingly, oncology led the pack. Cancer was the single most active therapeutic area with 161 deals, or 24 percent of all deals that were assigned a therapeutic area. This category, by the way, accounted for 29 percent of the aggregate deal sizes disclosed last year and is potentially worth $10 billion, based on 35 cancer deals that disclosed a deal size. And slightly more than half of the cancer deals were signed during the discovery or pre-clinical phases.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next